UKRI's Latest Push into Revolutionary Cancer Therapies

UK Research and Innovation (UKRI), the UK's primary funding body for research and innovation, has just announced funding for around thirty groundbreaking health projects, with tiny robots designed to treat cancer stealing the spotlight. Announced on March 23, 2026, this initiative highlights applicant-led ideas that blend multiple disciplines to tackle pressing health challenges. Among them, 'snailbots' – miniature soft robots inspired by snail locomotion – aim to deliver chemotherapy drugs directly to bowel cancer tumours, promising more effective treatment with fewer side effects on healthy tissues.

These projects fall under UKRI's Engineering and Physical Sciences Research Council (EPSRC) New Horizons programme, which supports bold, high-risk ideas with streamlined funding up to £200,000 per project for up to 24 months. The focus on health underscores UKRI's commitment to interdisciplinary innovation at UK universities, positioning higher education institutions as leaders in medical robotics.

Snailbots: Mimicking Nature for Precision Medicine

At the heart of this announcement is the University of Manchester's 'Snail-inspired Soft Robots for High Precision Drug Delivery to Malignant Tumours' project. These 'snailbots' draw inspiration from how snails move using muscular undulations in their foot combined with adhesive mucus, allowing precise, slow-speed navigation over rough terrains – perfect for the colon's folds.

The robots will be made from biocompatible peptide-based bionanomaterials that respond to external biofriendly triggers for remote control. Once deployed, they localise to the tumour, releasing drugs regionally to maximise bioavailability while minimising systemic exposure. This could transform bowel cancer therapy, where current chemotherapy often causes severe side effects due to non-specific delivery.

Principal Investigator Dr. Mostafa Nabawy, from Manchester's Department of Mechanical and Aerospace Engineering, leads a team including Co-Investigators Mohamed Elsawy, Katie Finegan, Lee Margetts, and William Sellers. Funded at £527,682 under UKRI's Cross Research Council Responsive Mode (CRCRM), the two-year project (June 2026–May 2028) will study snail biomechanics, develop simulations, prototype robots, and test them for colorectal applications.

Step-by-Step: Engineering Snailbots from Biology to Clinic

Developing these microrobots involves several key steps:

• Biomechanical Analysis: High-speed imaging and force measurements of live snails to model undulation and mucus adhesion under varied conditions.
• Material Innovation: Synthesising peptide-based soft materials mimicking snail mucus – adhesive, biocompatible, and trigger-responsive (e.g., to magnetic fields or ultrasound).
• Robot Design and Prototyping: Miniaturised actuators for foot-like undulations, integrated sensors for navigation, and drug reservoirs for controlled release.
• Digital Twin Simulation: Multiscale models using finite element analysis and machine learning to predict performance in physiological environments.
• In Vitro and Ex Vivo Testing: Validation in simulated colons, progressing to animal models for efficacy and safety.

This bio-mimetic approach addresses challenges like navigating mucosal barriers and withstanding peristalsis, peristaltic waves, and enzymes.

Bowel Cancer in the UK: Scale of the Challenge

Bowel cancer, also known as colorectal cancer, is the UK's fourth most common cancer, with nearly 50,000 new cases annually and over 17,000 deaths – the third leading cause of cancer mortality. Rates are projected to stabilise, but early detection remains crucial: 90% five-year survival if caught early vs. 10% for advanced stages.

Risk factors include age, diet, smoking, and genetics. Current screening via faecal immunochemical tests (FIT) detects blood but misses pre-cancerous polyps effectively. Surgical resection and chemotherapy dominate treatment, but recurrence rates are high (30–50%).

Limitations of Conventional Cancer Treatments

Systemic chemotherapy affects healthy cells, causing nausea, hair loss, and neuropathy. Targeted therapies like monoclonal antibodies help but fail in resistant cases. Endoscopy delivers drugs locally but is invasive. Microrobots offer untethered, autonomous navigation for precise, on-demand delivery – a paradigm shift.

Read more on microrobot advances in cancer therapy in this review from recent literature.

Photo by ling ze on Unsplash

Complementary UKRI Projects: A Robotics Ecosystem

UKRI's portfolio includes other robot innovations:

• Pancreatic Cancer Bacteria Bots: Engineered bacteria in ultrasound-activated gels to boost immune response.
• Musculoskeletal VR Assessment: Multimodal sensing for better arthritis rehab.

These exemplify UK higher education's role in translational research.

University of Leeds' Oloid Rolling Robot

The University of Leeds' Science and Technologies of Robotics in Medicine (STORM) Lab has developed an oloid-shaped magnetic endoscope (OME) for virtual biopsies. Published in Science Robotics (March 2025), this 21mm-diameter robot rolls via external magnets, integrating 28MHz ultrasound for 3D subsurface imaging of GI lesions.

Prof. Pietro Valdastri's team, with Nikita Greenidge as lead author, tested it in porcine models, identifying lesions instantly – no tissue removal needed. Human trials eyed for 2026. Check the full paper.

Nottingham's Snake-Like Robot for Bile Duct Cancer

Prof. Guru Aithal's 21-person team at the University of Nottingham received UKRI cross-council funding for a snake robot navigating bile ducts, mapping cholangiocarcinoma (bile duct cancer – rare but deadly), and deploying nanoparticle-loaded stents activated wirelessly to kill cells. Part of £32.4m for 36 projects.

Impacts on Patients, Economy, and Higher Education

These robots could cut treatment costs (bowel cancer: £1.2bn/year NHS), improve survival (early detection + targeted therapy), and reduce hospital stays. For UK universities, they attract talent, spin-outs (e.g., Leeds' Atlas Endoscopy), and global collaborations.

Stakeholders: Patients gain precision; clinicians, real-time data; researchers, interdisciplinary training.

Challenges, Ethics, and Road to Clinic

• Biocompatibility and scalability.
• Regulatory hurdles (MHRA approval).
• Ethical AI control in autonomy.
• Equity in access.

Solutions: Rigorous testing, public engagement, diverse teams. Trials 2027+.

Photo by Johnny Briggs on Unsplash

Career Opportunities in Medical Robotics

UK universities seek experts in robotics, biomaterials, AI. Roles: Postdocs, lecturers in mech eng, pharmacy. Explore research positions or higher ed jobs.

Skills: CAD, ML, biomech – demand surging with UKRI investments.